BOSTON — The first formal phase 1 study of mesenchymal stem cells for multiple sclerosis (MS) to be conducted in North America has shown no safety issues. "The goal was to show safety, feasibility and ...

Please provide your email address to receive an email when new articles are posted on . Top-line results of a phase 2 clinical trial for an adipose-derived autologous mesenchymal stem cell therapy to ...

Researchers from the Germans Trias i Pujol Research Institute (IGTP) have published a review analyzing the therapeutic ...

West Palm Beach, Florida — In an interim analysis of an extension study, intrathecal injection of autologous bone marrow–derived mesenchymal stem cells (MSCs) has been associated with favorable ...

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) ...

Multiple sclerosis is a devastating disease that has no cure. So when something comes along that offers hope, it garners worldwide attention. That’s the case with stem cell therapy for MS. But it’s ...